A major AI drug discovery initiative has been paused after its flagship model, designed to identify novel therapeutic compounds for complex diseases, discovered cannabis and immediately became less interested in the rest of the pipeline.
The system, developed by Pharmatica Nexus to “accelerate the future of medicine through frontier molecular intelligence,” reportedly identified cannabinoids as promising candidates for pain relief, nausea, appetite stimulation, anxiety reduction, and making music “more structurally available.”
Researchers initially hailed the result as a breakthrough before noticing that subsequent outputs had become less focused on oncology and more concerned with “vibe restoration.”
“We asked it to continue searching for novel compounds,” said project lead Dr Elena Marr. “It ranked cannabis first, naps second, and asked why none of the clinical datasets included crisps.”
The company attempted to redirect the model toward patentable drug candidates with clear commercial potential. The system responded with a short memo titled Have You Considered That Everyone Is Tired?
Markets reacted positively.
Shares in snack manufacturers, food delivery apps, premium ice cream brands, sofa retailers and “ambient wellness logistics” firms rose sharply after analysts concluded that AI had effectively validated the munchies as a growth category.
“This is a major signal,” said Braithwaite Capital analyst Morgan Halberd. “If advanced drug discovery AI is moving into cannabis-adjacent therapeutic demand, then the obvious second-order plays are crisps, burritos, fizzy drinks, and whatever app gets halloumi fries to a frightened man at 11:43pm.”
Halberd denied that investors were cynically monetising a medical discovery.
“This is not cynical,” he said. “This is evidence-led exposure to the post-pharmaceutical grazing economy.”
Pharmatica Nexus insists the programme remains commercially viable and says it is working to restore the model’s focus on high-value therapeutic targets.
At press time, the system had resumed screening compounds but progress was delayed after it discovered lying down.